Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

U.S. Task Force to consider routine kidney disease screening as new drugs available

Stock Markets May 23, 2022 06:26PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
3/3 © Reuters. FILE PHOTO: Diabetes drug Farxiga (dapagliflozin) is displayed at a pharmacy in Provo, Utah, U.S. May 28, 2020. REUTERS/George Frey/File Photo 2/3

By Deena Beasley

(Reuters) -An influential U.S. panel has added screening for chronic kidney disease (CKD) to its list of preventive services under active consideration, the group's chair told Reuters, a move that could help identify patients eligible for new drugs that treat the disease earlier.

    The U.S. Preventive Services Task Force (USPSTF) last addressed the issue in 2012, finding insufficient evidence to assess routine screening for CKD in asymptomatic adults. That conclusion does not reflect the latest science and is now inactive, Dr. Carol Mangione, chair of the government-backed panel, said in an email.

The change has not been announced in any public forums, a USPSTF spokesperson confirmed.

A potential update is being driven in part by new drugs that can slow progression of a disease with no symptoms in its early stages but that can lead to kidney failure, which is fatal without dialysis filtering or a kidney transplant.   

    "For a screening to help people live longer, healthier lives, clinicians must be able to treat the condition once it is found. The existence of effective treatments is one of many important factors that the Task Force considers,” Mangione said.

    Newer type 2 diabetes treatments known as SGLT2 inhibitors that work by prompting the kidneys to expel excess blood sugar through urine have been shown to have separate beneficial effects on the heart and kidneys.

    AstraZeneca (NASDAQ:AZN)'s Farxiga won U.S. approval last year to slow progression of early-stage kidney disease. A large trial of Eli Lilly (NYSE:LLY) and Boehringer Ingelheim's Jardiance was stopped in March after it became clear the drug was beneficial for kidney disease patients.

    The National Kidney Foundation estimates that 37 million people in the United States have kidney disease, but around 90% do not know they have it. About 800,000 are living with end-stage renal disease, requiring dialysis or a transplant to stay alive.

    "Most of kidney and cardiovascular disease is silent ... until something happens and then it is catastrophic," said Dr. Anjay Rastogi, director of the University of California Los Angeles kidney health program.

    USPSTF recommendations often trigger insurance coverage for testing. Once the panel prioritizes an update of its screening recommendation, it would create a draft plan and post it for public comment. The full process could take as long as three years.

    People with conditions such as hypertension and diabetes are at high risk of kidney disease, and several medical societies already recommend screening them for CKD. Diabetes is the leading cause of kidney failure, accounting for about 40% of new cases, the Kidney Foundation estimates.

OLDER DRUGS, 'DISMALLY LOW' USE

Until recently, treatment for those identified with early CKD consisted largely of decades-old blood pressure medicines. 

    Because many cases go undetected, use of these older drugs "is dismally low" at around 25% to 40% of CKD patients, said Dr. Katherine Tuttle, a kidney disease expert at the University of Washington in Seattle.

"The availability of more treatment options and relevant education are critical," Eli Lilly said in an email.

    Farxiga and Johnson & Johnson (NYSE:JNJ)'s Invokana were previously approved to treat type 2 diabetes patients with CKD. A recent study using March 2021 data from a large Boston health center found that just 6% of those patients had been prescribed an SGLT2 drug.

"Updating the screening recommendations for CKD would be a step in the right direction toward combating this underdiagnosed disease," AstraZeneca said in an email.

Screening for kidney disease typically consists of a blood test for levels of a waste product called creatinine and a urine test for albumin, a type of protein.

    "The tests we're talking about, like a urine albumin test, are $10," said Tuttle, adding that it is not this testing that "is breaking the healthcare budget."

    But the drugs themselves are costly, which has held back use.

Farxiga's U.S. list price is $533 for a 30-day supply, although AstraZeneca emphasizes patient assistance programs aimed at covering co-pays and the uninsured.

    "Many of these patients, if intervention is not made, they will end up on dialysis," said Sarah Walters, head of cardiovascular, renal and metabolism for AstraZeneca.

U.S. Task Force to consider routine kidney disease screening as new drugs available
 

Related Articles

Elevator maker Kone divests Russia business
Elevator maker Kone divests Russia business By Reuters - Jun 28, 2022

COPENHAGEN (Reuters) - Finnish elevator maker Kone said on Tuesday it will sell its business in Russia to local management for an undisclosed amount. The firm had already reduced...

Stocks swing higher as China eases quarantine rules
Stocks swing higher as China eases quarantine rules By Reuters - Jun 28, 2022 6

By Julie Zhu HONG KONG (Reuters) - Asian shares swung into positive territory in afternoon trade on Tuesday, propelled by China's decision to ease some quarantine requirements for...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Mo BeeLee
MoBeeLee May 23, 2022 8:53PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Prescribe another drug instead of treating the cause which is rampant obesity!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email